Neurofilaments as a biomarker of axonal loss in multiple sclerosis
Massoud, H., Eldeen, E., Khattab, S., Alazim, G. (2017). Neurofilaments as a biomarker of axonal loss in multiple sclerosis. EKB Journal Management System, 1(2), 63-68. doi: 10.4103/sjamf.sjamf_14_17
Hoda Mohamed Ali Massoud; Eman Mohamed Saif Eldeen; Sahar Saied Abd Khattab; Ghada Saed Abd Alazim. "Neurofilaments as a biomarker of axonal loss in multiple sclerosis". EKB Journal Management System, 1, 2, 2017, 63-68. doi: 10.4103/sjamf.sjamf_14_17
Massoud, H., Eldeen, E., Khattab, S., Alazim, G. (2017). 'Neurofilaments as a biomarker of axonal loss in multiple sclerosis', EKB Journal Management System, 1(2), pp. 63-68. doi: 10.4103/sjamf.sjamf_14_17
Massoud, H., Eldeen, E., Khattab, S., Alazim, G. Neurofilaments as a biomarker of axonal loss in multiple sclerosis. EKB Journal Management System, 2017; 1(2): 63-68. doi: 10.4103/sjamf.sjamf_14_17

Neurofilaments as a biomarker of axonal loss in multiple sclerosis

The Scientific Journal of Al-Azhar Medical Faculty, Girls
Volume 1, Issue 2, September 2017, Page 63-68  XML PDF (1.13 MB)
DOI: 10.4103/sjamf.sjamf_14_17
View on SCiNiTO View on SCiNiTO
Authors
Hoda Mohamed Ali Massoud; Eman Mohamed Saif Eldeen; Sahar Saied Abd Khattab; Ghada Saed Abd Alazim
Abstract
Background
Neurofilaments (NF-H) might be a potential biomarker of CNS tissue damage in MS, but their potential predictive value for the future disease course, disability, disease progression, and treatment response needs to be investigated.
Aim of the work
The aim of this study is to evaluate the role of serum phosphorylated neurofilament H as a marker in multiple sclerosis and correlate it's level with clinical expanded disability status scale (EDSS) and magnetic resonance imaging findings.
Subjects and methods
Study included 40 patients and 20 healthy control, 20 patients with relapsing remitting multiple sclerosis (RRMS) and 20 patients with secondary progressive multiple sclerosis (SPMS). All patients in this study were subjected to full history taking and clinical examination and scoring according to the EDSS scores, routine laboratory investigations, measuring of serum phosphorylated neurofilament-H (PNF-H) levels and neuroradiological assessment.
Results
Patients with secondary progressive multiple sclerosis were more likely to have a high serum (PNF-H) titer compared to patients with relapsing remitting multiple sclerosis, and these levels were significantly correlated with EDSS scores in both patients groups.
Conclusion
The increase in (PNF-H) titer during the progressive phase of the disease together with the correlation of (PNF-H) levels with all clinical scales and radiological lesions (e.g. gadolinium-enhanced lesions and black holes) suggests that cumulative axonal loss is responsible for sustained disability and that high (PNF-H) level is a poor prognostic sign.
Keywords
axonal damage; Multiple sclerosis; neurofilament-H
Statistics
Article View: 21
PDF Download: 19